Innovation & Enterprise


UCL gene therapy spinout Freeline announces initial public offering (IPO)

7 August 2020

Freeline Therapeutics develops cures for a wide range of liver-based diseases which have previously been under-served and incurable.

DNA helix

Freeline Therapeutics has announced the pricing of its initial public offering (IPO) in the United States. 8,823,529 shares were made available at $18 each. This means the company raised approximately $158.8 million via the IPO.

Freeline’s gene therapy uses adeno-associated virus (AAV)-based technology to deliver safe and effective gene replacement to the liver for diseases like haemophilia B and Fabry. Gene therapy has the potential to provide long-term benefit to patients from a single treatment by carrying a therapeutic gene to a target cell in the body.

Freeline Therapeutics was founded in 2015 by UCLB, the commercialisation arm of UCL and part of UCL Innovation & Enterprise, and Syncona LLP. The company has received significant funding from the UCL Technology Fund (managed by AlbionVC in collaboration with UCLB). The UCL spinout’s focus is to develop and commercialise gene therapies for bleeding and other debilitating disorders. 

Freeline’s pioneering gene therapy treatments build on the work of founder and CSO, Professor Amit Nathwani, UCL Cancer Institute. 


Find out more about:

Image credit: iStock.com/koto_feja